PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 136 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2015. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $71,000 | -4.1% | 8,000 | 0.0% | 0.00% | – |
| Q1 2021 | $74,000 | -7.5% | 8,000 | 0.0% | 0.00% | – |
| Q4 2020 | $80,000 | +2.6% | 8,000 | 0.0% | 0.00% | – |
| Q3 2020 | $78,000 | +77.3% | 8,000 | +55.1% | 0.00% | – |
| Q4 2019 | $44,000 | -71.1% | 5,158 | -62.2% | 0.00% | -100.0% |
| Q3 2019 | $152,000 | -46.1% | 13,658 | -38.4% | 0.00% | 0.0% |
| Q2 2019 | $282,000 | -38.8% | 22,158 | +111.0% | 0.00% | -66.7% |
| Q1 2019 | $461,000 | +153.3% | 10,500 | +23.5% | 0.00% | +200.0% |
| Q4 2018 | $182,000 | -60.5% | 8,500 | -19.0% | 0.00% | -66.7% |
| Q3 2018 | $461,000 | -24.3% | 10,500 | -2.8% | 0.00% | -25.0% |
| Q2 2018 | $609,000 | -21.8% | 10,800 | -8.5% | 0.00% | -20.0% |
| Q1 2018 | $779,000 | +281.9% | 11,800 | +337.0% | 0.01% | +150.0% |
| Q3 2015 | $204,000 | -32.7% | 2,700 | +3.8% | 0.00% | -50.0% |
| Q2 2015 | $303,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |